Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 51780
Gene Symbol: KDM3B
KDM3B
0.200 Biomarker group RGD [Olygopeptide KND as a putative endogenous prototype of delta sleep inducing peptide (DSIP). Comparative study of biological properties]. 24397026 2014
Entrez Id: 414
Gene Symbol: ARSD
ARSD
0.100 AlteredExpression group BEFREE Youth with ASD without co-occurring intellectual disability experience high levels of intolerance of uncertainty (IU), which is related to anxiety. 29316350 2018
Entrez Id: 2316
Gene Symbol: FLNA
FLNA
0.010 Biomarker group BEFREE Working adults (n = 496, 67.5% female, 78.6% white, mean age 48.7 [SD, 10.8] years, body mass index 28.2 [SD, 6.7] kg/m, diabetes 5.8%, hypertension 20.0%, hyperlipidemia 17.9%, heart disease 2.6%) enrolled in the Emory-Georgia Tech Predictive Health Institute study completed baseline demographic, clinical, depression (Beck Depression Inventory II), anxiety (General Anxiety Disorder 7), sleep (Pittsburg Sleep Quality Index), and noninvasive endothelial function (brachial artery flow-mediated dilation [FMD]) measures. 26488555 2018
Entrez Id: 2489
Gene Symbol: FSHMD1A
FSHMD1A
0.010 Biomarker group BEFREE Working adults (n = 496, 67.5% female, 78.6% white, mean age 48.7 [SD, 10.8] years, body mass index 28.2 [SD, 6.7] kg/m, diabetes 5.8%, hypertension 20.0%, hyperlipidemia 17.9%, heart disease 2.6%) enrolled in the Emory-Georgia Tech Predictive Health Institute study completed baseline demographic, clinical, depression (Beck Depression Inventory II), anxiety (General Anxiety Disorder 7), sleep (Pittsburg Sleep Quality Index), and noninvasive endothelial function (brachial artery flow-mediated dilation [FMD]) measures. 26488555 2018
Entrez Id: 2332
Gene Symbol: FMR1
FMR1
0.400 Biomarker group BEFREE Women with the FMR1 premutation appear to have a high incidence of depression and increased symptoms of anxiety. 20629912 2010
Entrez Id: 340075
Gene Symbol: ARSI
ARSI
0.100 GeneticVariation group BEFREE Women with breast cancer (n = 749) were enrolled the week prior to surgery and required to complete a demographic questionnaire, the Chinese version of Neuroticism subscale of NEO-Five Factor Inventory (CV-N-NEO-FFI), Anxiety Sensitivity Index-3 (CV-ASI-3), and Life Orientation Test-Revised (CV-LOT-R). 30560420 2019
Entrez Id: 90993
Gene Symbol: CREB3L1
CREB3L1
0.010 Biomarker group BEFREE Women who had significantly higher OASIS (anxiety) scores (β = .530, p < .001), PHQ9 (depression) scores (β = .496, p < .001), and EPDS (postpartum depression and anxiety) scores (β = .585, p < .001) also had elevated total PSQI scores after adjustment for covariates, including prenatal depression and anxiety scores. 30030650 2018
Entrez Id: 3855
Gene Symbol: KRT7
KRT7
0.100 GeneticVariation group BEFREE Women completed standardised questionnaires regarding psychosocial burden (SCL-R 90), fear of childbirth (W-DEQ) and anxiety (STAI), personality structure (HEXACO-Pi-R), and ambiguity tolerance (PFI, PNS, and NFC), social support (F-SozU) as well as one questionnaire assessing demographic parameters and further factors potentially influencing their choice of the mode of delivery. 29344846 2018
Entrez Id: 51540
Gene Symbol: SCLY
SCLY
0.100 GeneticVariation group BEFREE Women completed standardised questionnaires regarding psychosocial burden (SCL-R 90), fear of childbirth (W-DEQ) and anxiety (STAI), personality structure (HEXACO-Pi-R), and ambiguity tolerance (PFI, PNS, and NFC), social support (F-SozU) as well as one questionnaire assessing demographic parameters and further factors potentially influencing their choice of the mode of delivery. 29344846 2018
Entrez Id: 6886
Gene Symbol: TAL1
TAL1
0.100 GeneticVariation group BEFREE Women completed standardised questionnaires regarding psychosocial burden (SCL-R 90), fear of childbirth (W-DEQ) and anxiety (STAI), personality structure (HEXACO-Pi-R), and ambiguity tolerance (PFI, PNS, and NFC), social support (F-SozU) as well as one questionnaire assessing demographic parameters and further factors potentially influencing their choice of the mode of delivery. 29344846 2018
Entrez Id: 4477
Gene Symbol: MSMB
MSMB
0.020 Biomarker group BEFREE Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID). 31370823 2019
Entrez Id: 89782
Gene Symbol: LMLN
LMLN
0.010 Biomarker group BEFREE Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID). 31370823 2019
Entrez Id: 84000
Gene Symbol: TMPRSS13
TMPRSS13
0.010 Biomarker group BEFREE Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID). 31370823 2019
Entrez Id: 4485
Gene Symbol: MST1
MST1
0.010 Biomarker group BEFREE Within the ID cohort, behaviour impairment and MSP (i.e. moderate, severe, or profound) ID was associated with increased prescription of anxiolytics, both among those with anxiety (1.15 [1.03-1.30] for behaviour impairment and 1.23 [1.10-1.38] for MSP ID) and among those with mood disorders (1.14 [0.97-1.35] for behaviour impairment and 1.26 [1.04-1.52] for MSP ID). 31370823 2019
Entrez Id: 1813
Gene Symbol: DRD2
DRD2
0.400 GeneticVariation group BEFREE Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that craving, irritability, and anxiety were significantly attenuated only among subjects with DRD2-Taq1 A2/A2 genotypes. 14668077 2003
Entrez Id: 348
Gene Symbol: APOE
APOE
0.100 GeneticVariation group BEFREE While some studies failed to find a significant association between the APOE polymorphism and NPS in late-onset AD, other studies reported a significant association between the APOE ɛ4 allele and an increase in agitation/aggression, hallucinations, delusions, and late-life depression or anxiety. 21763789 2012
Entrez Id: 3350
Gene Symbol: HTR1A
HTR1A
0.300 Biomarker group BEFREE While multiple lines of evidence implicate the 5-HT1A receptor in the pathophysiology of anxiety and depression as well as in the mechanism of action of anxiolytics/antidepressants, its relevance to the therapeutic effectiveness of these drugs has been a matter of considerable debate (for review see Griebel, 1995; Hensler, 2003; Hjorth et al., 2000; Lesch et al., 2003). 15683551 2004
Entrez Id: 675
Gene Symbol: BRCA2
BRCA2
0.030 GeneticVariation group BEFREE While breast MRI surveillance did not have a detrimental psychological impact on women with a BRCA1 or BRCA2 mutation, recalling these very high-risk women for further imaging after a false positive MRI scan temporarily increased their global anxiety. 21612928 2011
Entrez Id: 672
Gene Symbol: BRCA1
BRCA1
0.080 GeneticVariation group BEFREE While breast MRI surveillance did not have a detrimental psychological impact on women with a BRCA1 or BRCA2 mutation, recalling these very high-risk women for further imaging after a false positive MRI scan temporarily increased their global anxiety. 21612928 2011
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.020 Biomarker group BEFREE When compared with placebo or other antihypertensive medications, AT1R blockers and angiotensin converting enzyme inhibitors were associated with improved overall quality of life (standard mean difference = 0.11, 95% confidence interval = [0.08, 0.14], p < 0.0001), positive wellbeing (standard mean difference = 0.11, 95% confidence interval = [0.05, 0.17], p < 0.0001), mental (standard mean difference = 0.15, 95% confidence interval = [0.06, 0.25], p < 0.0001), and anxiety (standard mean difference = 0.08, 95% confidence interval = [0.01, 0.16], p < 0.0001) domains of QoL. 28754072 2018
Entrez Id: 185
Gene Symbol: AGTR1
AGTR1
0.020 Biomarker group BEFREE When compared with placebo or other antihypertensive medications, AT1R blockers and angiotensin converting enzyme inhibitors were associated with improved overall quality of life (standard mean difference = 0.11, 95% confidence interval = [0.08, 0.14], p < 0.0001), positive wellbeing (standard mean difference = 0.11, 95% confidence interval = [0.05, 0.17], p < 0.0001), mental (standard mean difference = 0.15, 95% confidence interval = [0.06, 0.25], p < 0.0001), and anxiety (standard mean difference = 0.08, 95% confidence interval = [0.01, 0.16], p < 0.0001) domains of QoL. 28754072 2018
Entrez Id: 6532
Gene Symbol: SLC6A4
SLC6A4
0.600 GeneticVariation group BEFREE We used different statistical analyses to test co-development of cannabis use and symptoms of anxiety throughout adolescence and the possible role of the 5-HTTLPR genotype in this process. 26860734 2017
Entrez Id: 79694
Gene Symbol: MANEA
MANEA
0.010 GeneticVariation group BEFREE We used a multi-stage association study approach starting with four psychiatric disorders to show an association between a MANEA single-nucleotide polymorphism (SNP; rs1133503) and anxiety disorders. 24473444 2014
Entrez Id: 130497
Gene Symbol: OSR1
OSR1
0.030 GeneticVariation group BEFREE We use diagnostic interviews to assess anxiety (specific phobia, separation anxiety disorder, social phobia, generalized anxiety disorder, obsessive-compulsive disorder, and agoraphobia) and externalizing disorders (attention deficit hyperactivity disorder; ADHD, and oppositional defiant disorder; ODD). 30336382 2018
Entrez Id: 3350
Gene Symbol: HTR1A
HTR1A
0.300 GeneticVariation group BEFREE We thus conducted a structural equation model (SEM) to examine whether the HTR1A rs6295 variant can affect anxiety by altering parasympathetic nervous activity. 29363117 2018